| 26.04 03:36 | dpa-AFX: Biogen's Tofidence Gets Positive CHMP Opinion For Rheumatoid Arthritis,Juvenile Arthritis & COVID-19 |
| 25.04 22:05 | dpa-AFX: GNW-Adhoc: Biogen Receives Positive CHMP Opinion for TOFIDENCET (tocilizumab), a Biosimilar Referencing ROACTEMRA® |
| 25.04 09:49 | dpa-AFX: *DZ BANK SENKT FAIREN WERT FÜR BIOGEN AUF 214 (236) USD - 'HALTEN' |
| 25.04 09:49 | dpa-AFX: *DZ BANK CUTS FAIR VALUE FOR BIOGEN TO 214 (236) USD - 'HOLD' |
| 24.04 13:16 | dpa-AFX: Biogen Q1 Adj. EPS Tops Estimates, But Sales Miss; Reaffirms FY24 Outlook |
| 24.04 13:13 | dpa-AFX: *BIOGEN Q1 NET INCOME ATTRIBUTABLE TO BIOGEN $393.4 MLN VS $387.9 MLN LAST YEAR |
| 24.04 13:11 | dpa-AFX: *BIOGEN Q1 TOTAL REVENUE $2.29 BLN VS $2.463 BLN LAST YEAR |
| 24.04 13:11 | dpa-AFX: *BIOGEN CONTINUES TO EXPECT FY OPERATING INCOME TO GROW LOW-DOUBLE DIGIT PERCENTAGE |
| 24.04 13:10 | dpa-AFX: *BIOGEN CONTINUE TO EXPECT FY TOTAL REVENUE TO DECLINE BY A LOW- TO MID-SINGLE DIGIT PERCENTAGE |
| 24.04 13:10 | dpa-AFX: *BIOGEN REAFFIRMS 2024 FINANCIAL GUIDANCE: NON-GAAP EPS OF $15.00 TO $16.00 |
| 24.04 13:04 | dpa-AFX: *BIOGEN Q1 GAAP EPS $2.70; NON-GAAP EPS $3.67 |
| 24.04 12:01 | dpa-AFX: Biogen Q1 24 Earnings Conference Call At 8:30 AM ET |
| 01.04 02:50 | dpa-AFX: Eisai Submits Leqembi SBLA For IV Maintenance Dosing In Early Alzheimer's Disease |
| 01.04 02:34 | dpa-AFX: *EISAI COMPLETES SUBMISSION OF LEQEMBI SBLA FOR IV MAINTENANCE DOSING FOR TREATMENT OF EARLY ALZHEIMER'S DISEASE TO FDA |
| 08.03 22:10 | MÄRKTE USA/Gewinnmitnahmen - US-Arbeitsmarkt ungebrochen robust |
| 08.03 18:06 | MÄRKTE USA/Gewinnmitnahmen - US-Arbeitsmarkt hartnäckig robust |
| 08.03 15:37 | dpa-AFX: *BIOGEN +1,9% - RBC: 'VERZÖGERUNG BEI ELI LILLY VON VORTEIL FÜR MITTEL LEQEMBI' |
| 08.03 13:28 | dpa-AFX: *BIOGEN VORBÖRSLICH +3,7% NACH VERZÖGERTER FDA-ENTSCHEIDUNG FÜR ELI-LILLY-MITTEL |
| 06.03 13:30 | dpa-AFX: GNW-Adhoc: New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy |
| 04.03 22:16 | dpa-AFX: GNW-Adhoc: Biogen Highlights New Data at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PDT) 2024 Annual Meeting |
|
|
